Magle Chemoswed Holding AB (publ) (STO:MAGLE)

Market Cap	30.26M -94.4%
Revenue (ttm)	273.25M -4.1%
Net Income	-180.73M
EPS	-8.74
Shares Out	30.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,055
Open	1.050
Previous Close	1.000
Day's Range	1.050 - 1.300
52-Week Range	0.865 - 27.000
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 24, 2026

About STO:MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 150
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 20, 2026

Data Sources Report a data error